MSH|^~\&|MIC|ARH|||201912091251||ORU^R01|4125860|D|2.3|||AL|NE
PID|1||AB00007889|AB7847|PHATEST^BRITISH^COLUMBIAN||19540101|F||||||||||AB001007/18|9875497092
OBR|1|36598^MIC|00027741^19:B0000357R^MIC^19:B357^36598|100.5005^BC^Blood culture^^^600-7||201912091244|201912090700|||||||201912090705|Blood^^^Peripheral|||||||||MB|I||||
OBX|1|CE|100.5010^BCT^Blood culture^^6463-4^600-7^O:ECOL|1.1|ECOL^Escherichia coli||||||F|||201912091251
OBX|2|ST|100.5010^BCT^Blood culture^^6463-4^600-7|1.1|||||||F|||201912091251
NTE|1||This organism has an extended spectrum beta-lactamase
NTE|2||(ESBL).
NTE|3||Patients may require contact precautions if they have risk
NTE|4||factors for transmission. Contact Infection Prevention and
NTE|5||Control for further information.
NTE|6||A copy of these results has been sent to Infection
NTE|7||Prevention and Control.
OBR|2||00027741^19:B0000357R^MIC^19:B357^36598|903.3150^N391^Vitek N391 Sensitivity^^^29576-6||201912091244|201912090700|||||||201912090705|Blood^^^Peripheral|||||||||MB|I|6463-4^1.1|||36598^MIC
OBX|1|ST|100.000^MER^Meropenem^^6652-2^6652-2|||||S|||F|||201912091251
OBX|2|ST|100.500^CAX^Ceftriaxone^^141-2^141-2|||||R|||F|||201912091251
OBX|3|ST|101.000^CFZ^Cefazolin^^76-0^76-0|||||I|||F|||201912091251
OBX|4|ST|200.100^AM^Ampicillin^^28-1^28-1|||||R|||F|||201912091251
OBX|5|ST|300.000^AK^Amikacin^^12-5^12-5|||||I|||F|||201912091251
OBX|6|ST|300.100^TO^Tobramycin^^508-2^508-2|||||I|||F|||201912091251
OBX|7|ST|300.200^GM^Gentamicin^^267-5^267-5|||||I|||F|||201912091251
OBX|8|ST|500.650^CP^Ciprofloxacin^^185-9^185-9|||||R|||F|||201912091251
OBX|9|ST|600.000^TS^Trimethoprim/sulfamethoxazole^^516-5^516-5|||||I|||F|||201912091251